Advocates of microdosing GLP-1 suggest several potential advantages, primarily centred on reducing the gastrointestinal side effects commonly associated with standard doses
A recent study indicated that patients with and without type 2 diabetes, 47% and 65% respectively, reported stopping the use of their GLP-1s within one year
Yet compared with eligible White individuals, larger proportions of Black and Hispanic individuals have potential barriers to GLP-1 access, such as being uninsured, lacking a regular provider, having low income, or lacking higher education [231]
Samms RJ, et al
Similarly, semaglutide ameliorates doxorubicin-induced cardiotoxicity by reducing BNIP3-mediated mitochondrial dysfunction through the PI3K/AKT pathway, enhancing mitochondrial function and reducing cardiac injury (Li et al., 2024), potentiating its clinical application in cardiovascular diseases
It signals fullness to the brain, potentially leading to reduced food intake and weight loss